Prostate Cancer
Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients - Abstract
September 25, 2014
Cardiovascular risk profile of veteran men beginning androgen deprivation therapy - Abstract
September 25, 2014
New era of the treatment of CRPC in Japan - Abstract
September 25, 2014
Predicting the Gleason sum of a patient with a prostate biopsy core Gleason ≤ 7 and a prostate biopsy core Gleason ≥ 8 - Abstract
September 25, 2014
Effect of histological inflammation on total and free serum prostate-specific antigen values in patients without clinically detectable prostate cancer - Abstract
September 25, 2014
Resource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities - Abstract
September 25, 2014
Enzalutamide in European and North American men participating in the AFFIRM trial - Abstract
September 25, 2014
Prostate pointers and pitfalls: The 10 most prevalent problems in prostate biopsy interpretation - Abstract
September 24, 2014
Utility of an initial adaptive bladder volume control with ultrasonography for proton-beam irradiation for prostate cancer - Abstract
September 24, 2014
Maximum tumor diameter adjusted to the risk profile predicts biochemical recurrence after radical prostatectomy - Abstract
September 24, 2014
How to minimize lymphoceles and treat clinically symptomatic lymphoceles after radical prostatectomy - Abstract
September 24, 2014
Affecting African American men's prostate cancer screening decision-making through a mobile tablet-mediated intervention - Abstract
September 24, 2014
Prevention of erectile dysfunction after radiotherapy for prostate cancer - Abstract
September 24, 2014